EXTENDED TREATMENT WITH ANTI-THYMOCYTE GLOBULIN (ATGAM) IN RENAL-ALLOGRAFT RECIPIENTS

被引：25

作者：

WECHTER, WJ

MORRELL, RM

BERGAN, J

ROSENBERG, JC

TURCOTTE, J

SCHULTZ, JR

机构：

[1] NORTHWESTERN UNIV,DEPT SURG,CHICAGO,IL 60611

[2] WAYNE STATE UNIV,HUNTZEL HOSP SURG UNIT,DETROIT,MI 48202

[3] UNIV MICHIGAN,MED CTR,DEPT SURG,ANN ARBOR,MI 48109

来源：

TRANSPLANTATION | 1979年 / 28卷 / 05期

关键词：

D O I：

10.1097/00007890-197911000-00003

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Twenty renal allograft recipients were treated with antithymocyte globulin (ATGAM; ATG) for up to 16 weeks in addition to azathioprine and prednisone, while 20 controls received no ATG. The ATG group showed a lower incidence of first rejection episodes during the first month after transplantation, and also a better functional graft survival rate up to 2 years after transplantation. The results in this early ATG trial were better than those in subsequent trials which used 14-day treatment regimens. Longer treatment deserves another look. © 1979 by The Williams and Wilkins Co.

引用

页码：365 / 367

页数：3

共 7 条

[1]

BRADLEY J. V., 1968, DISTRIBUTION FREE ST

[2]

BUTT KMH, 1978, KIDNEY INT, V13, pS95

[3]

COSIMI AB, 1976, SURGERY, V80, P155

[4]

KOUNTZ SL, 1977, TRANSPLANT P, V9, P1023

[5]

THOMAS F, 1977, LANCET, V2, P672

[6] ANTI-THYMOCYTE GLOBULIN (ATGAM) IN RENAL-ALLOGRAFT RECIPIENTS - MULTICENTER TRIALS USING A 14-DOSE REGIMEN [J].

WECHTER, WJ ;

BRODIE, JA ;

MORRELL, RM ;

RAFI, M ;

SCHULTZ, JR .

TRANSPLANTATION, 1979, 28 (04) :294-302

[7] MANUFACTURE OF ANTI-THYMOCYTE GLOBULIN (ATGAM) FOR CLINICAL-TRIALS [J].

WECHTER, WJ ;

NELSON, JW ;

PERPER, RJ ;

PARCELLS, AJ ;

RIEBE, KW ;

EVANS, JS ;

SATOH, PS ;

KO, H .

TRANSPLANTATION, 1979, 28 (04) :303-307

← 1 →